Steifel Rides Ailing Barrier Into Pediatrics Market
Executive Summary
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the In Vivo blog. Visit the blog at http://invivoblog.blogspot.com/.
You may also be interested in...
GlaxoSmithKline Buys Back Into Dermatology With $2.9 Billion Stiefel Deal
Acquisition more than doubles GSK’s dermatology sales to $1.5 billion, creating a global specialist business across prescription and OTC drugs.
GlaxoSmithKline Buys Back Into Dermatology With $2.9 Billion Stiefel Deal
Acquisition more than doubles GSK’s dermatology sales to $1.5 billion, creating a global specialist business across prescription and OTC drugs.
Phase III Data With Scar Therapy Still Distant, Renovo Draws A Suitor
Pivotal results not due until 2011 – and skin peel drug needs a makeover.